文献速递血管炎

巨细胞动脉炎患者糖皮质激素治疗相关的严重不良事件:巢式病例对照分析

Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
PubMed 文献 · Semin Arthritis Rheum · 2016-11-28

本研究基于英国临床实践研究数据链(CPRD),在巨细胞动脉炎(GCA)患者中开展巢式病例对照分析,评估泼尼松龙剂量与糖尿病、青光眼、骨质疏松、骨折、严重感染住院及死亡风险的关系。多因素分析显示,随累积剂量增加,糖尿病和骨质疏松风险呈上升趋势;最高日均剂量(30mg/d)组相比低剂量(5mg/d)组,上述所有不良结局风险均显著升高。

要点

  • 泼尼松龙累积剂量增加与糖尿病、骨质疏松风险呈趋势相关(ptrend<0.05)。
  • 日均30mg/d组相比5mg/d组,糖尿病风险调整OR为4.7(95%CI 2.8-7.8)。
  • 日均30mg/d组严重感染住院风险调整OR为3.3(95%CI 2.2-5.2),死亡风险调整OR为2.1(95%CI 1.3-3.5)。

核心结论

  • 相比较低日均泼尼松龙剂量,高日均剂量与严重不良事件风险增加相关。

研究设计与样本

  • 基于英国临床实践研究数据链(CPRD)的GCA患者巢式病例对照分析,采用条件 logistic 回归计算未调整和多因素OR及95%CI。

主要发现

  • 多因素分析中,随口服泼尼松龙累积剂量增加,糖尿病和骨质疏松风险呈上升趋势(ptrend<0.05)。
  • 日均泼尼松龙30mg/d组相比5mg/d组,糖尿病调整OR为4.7(95%CI 2.8-7.8)。
  • 日均泼尼松龙30mg/d组相比5mg/d组,骨质疏松调整OR为1.9(95%CI 1.2-2.9)。
  • 日均泼尼松龙30mg/d组相比5mg/d组,骨折调整OR为2.6(95%CI 1.6-4.3)。
  • 日均泼尼松龙30mg/d组相比5mg/d组,青光眼调整OR为3.5(95%CI 2.0-6.1),严重感染调整OR为3.3(95%CI 2.2-5.2),死亡调整OR为2.1(95%CI 1.3-3.5)。

关键数值与推荐

  • 最高日均剂量类别为30mg/d,较低日均剂量类别为5mg/d,比较组间风险差异。
  • 累积泼尼松龙剂量增加与糖尿病、骨质疏松风险的趋势检验ptrend<0.05。

临床怎么用

  • 在GCA患者中使用高日均剂量泼尼松龙时,应警惕糖尿病、骨质疏松、骨折、青光眼、严重感染和死亡风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries. High-dose oral glucocorticoids (GCs) are the mainstay of GCA therapy. Using data from the UK Clinical Practice Research Datalink (CPRD), we examined the risk of oral GC-related serious adverse events (SAEs) in a UK population of patients with giant cell arteritis (GCA). METHODS: We conducted a series of nested case-control analyses in GCA patients to examine the effect of increasing dose of prednisolone on the risk of developing diabetes, glaucoma, osteoporosis, fractures, serious infection requiring hospitalization, and death. We used conditional logistic regression to calculate the unadjusted and multivariate odds ratios (ORs) with 95% CIs for the associations between prednisolone use and the risks of all outcomes of interest. We stratified the analyses by increasing cumulative prednisolone use and average daily dose. RESULTS: In the multivariate analyses, we observed a trend of increasing risk of diabetes and osteoporosis with increasing cumulative dose of oral prednisolone (ptrend < 0.05). GCA patients in the highest daily dose category (30mg/d) had an increased risk of diabetes (adjusted OR, 95% CI) (4.7, 2.8-7.8), osteoporosis (1.9, 1.2-2.9), fractures (2.6, 1.6-4.3), glaucoma (3.5, 2.0-6.1), serious infection (3.3, 2.2-5.2), and death (2.1, 1.3-3.5) compared to those with lower average daily prednisolone doses (5mg/d). CONCLUSION: Compared to lower average daily prednisolone doses, high average daily doses were associated with an increased risk of serious adverse effects.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Wilson JC, Sarsour K, Collinson N, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis. Semin Arthritis Rheum. 2016. PMID: 28040244. doi:10.1016/j.semarthrit.2016.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。